Core B exists to meet all of the cell culture and molecular biological needs of the COBRE Principal Investigators who are not routinely utilizing these methods in their own laboratories. This will ensure that each Investigator uses cellular and molecular regent that have been extensively characterized by the Core. The specific cell types and vectors are listed below. Core B will provide pluripotent E14 cerebral cortical- derived stem cells, neuron-restricted E14 spinal cord-derived stem cells, as well as genetically modified stem cells (see below) to all investigators as needed. Core B will construct required recombinant retroviruses, produce and titer the needed viral supernatants and infect any stem cell as required. A list of the cDNAs that are either in the retroviral vector or are presently being constructed is detailed below. These genetically modified cells will then be given to the COBRE Principal Investigators for their respective in vitro and/or in vivo assays. Core B will provide all recombinant adenoviral vectors that are needed by the COBRE Principal Investigators. Core B will enrich by fluorescence activated cell sorting (FACS) any stem cell populations expressing specific transgenes as required by the COBRE Principal Investigators. This Core will enable the Projects that use this Core to receive identical cells and vectors and will facilitate interaction between the respective Principal Investigators. It is expected that such interactions will make the COBRE Investigators more productive.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR015576-03
Application #
6630072
Study Section
Special Emphasis Panel (ZRR1)
Project Start
2002-08-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Louisville
Department
Type
DUNS #
City
Louisville
State
KY
Country
United States
Zip Code
40292
Kuypers, Nicholas J; Bankston, Andrew N; Howard, Russell M et al. (2016) Remyelinating Oligodendrocyte Precursor Cell miRNAs from the Sfmbt2 Cluster Promote Cell Cycle Arrest and Differentiation. J Neurosci 36:1698-710
Myers, Scott A; Bankston, Andrew N; Burke, Darlene A et al. (2016) Does the preclinical evidence for functional remyelination following myelinating cell engraftment into the injured spinal cord support progression to clinical trials? Exp Neurol 283:560-72
Ward, P J; Herrity, A N; Harkema, S J et al. (2016) Training-Induced Functional Gains following SCI. Neural Plast 2016:4307694
May, Zacnicte; Fouad, Karim; Shum-Siu, Alice et al. (2015) Challenges of animal models in SCI research: Effects of pre-injury task-specific training in adult rats before lesion. Behav Brain Res 291:26-35
Jagadapillai, Rekha; Mellen, Nicholas M; Sachleben Jr, Leroy R et al. (2014) Ceftriaxone preserves glutamate transporters and prevents intermittent hypoxia-induced vulnerability to brain excitotoxic injury. PLoS One 9:e100230
Nielson, Jessica L; Guandique, Cristian F; Liu, Aiwen W et al. (2014) Development of a database for translational spinal cord injury research. J Neurotrauma 31:1789-99
Ward, Patricia J; Herrity, April N; Smith, Rebecca R et al. (2014) Novel multi-system functional gains via task specific training in spinal cord injured male rats. J Neurotrauma 31:819-33
Kuypers, Nicholas J; James, Kurtis T; Enzmann, Gaby U et al. (2013) Functional consequences of ethidium bromide demyelination of the mouse ventral spinal cord. Exp Neurol 247:615-22
Schultz, R L; Kullman, E L; Waters, R P et al. (2013) Metabolic adaptations of skeletal muscle to voluntary wheel running exercise in hypertensive heart failure rats. Physiol Res 62:361-9
Burke, Darlene A; Whittemore, Scott R; Magnuson, David S K (2013) Consequences of common data analysis inaccuracies in CNS trauma injury basic research. J Neurotrauma 30:797-805

Showing the most recent 10 out of 150 publications